Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1382&sort=-keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1381&sort=-keywords" }, "data": [ { "type": "Grant", "id": "10331", "attributes": { "award_id": "1U18FD007725-01", "title": "Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-08-31", "award_amount": 50938, "principal_investigator": { "id": 26293, "first_name": "Stephen Douglas", "last_name": "Cole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26294, "first_name": "Elizabeth M.", "last_name": "Lennon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoonotic disease that, in addition to its importance in the human pandemic, has caused spillover infection and onward spread in mink, white-tailed deer, and hamsters. New viral variants with different characteristics are constantly emerging, with different characteristics and in some cases, these variants are able to infect species of animals that were not originally susceptible. Therefore, ongoing surveillance through Vet-LIRN is essential for early recognition of spread within animals. Given that companion animals reside in 85 million US households, if SARS-CoV-2 were to gain the ability to spread amongst pets or between pets and humans, there could be immense public health consequence and consequence to wildlife populations. The objective of this proposal is to evaluate and validate novel testing methodologies including validating loop-mediated isothermal amplification (LAMP) in a variety of sample matrices in dogs and cats, and to perform rigorous evaluation of a commercially available ELISA kit. Our specific aims include: Aim 1: Assess the validity of a commercial colorimetric LAMP assay for the qualitative detection of SARS-CoV-2 RNA in 4 novel matrices collected from both dogs and cats. Aim 2: Validate a commercially available ELISA for SARS-CoV-2 antibodies in dogs and cats while building capacity to conduct SARS-CoV-2 serological testing. These aims will provide technician training, equipment, and expertise to provide capacity for SARS-CoV-2 testing in dogs and cats.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10340", "attributes": { "award_id": "1U01FD007689-01", "title": "Development and Experimental Verification of Fundamental Models to Enable Implementation of Microwave-Assisted Freeze Drying", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26302, "first_name": "Vivian", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 999448, "principal_investigator": { "id": 26303, "first_name": "Emily S", "last_name": "Gong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1919, "ror": "", "name": "PHYSICAL SCIENCES, INC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Physical Sciences Inc. (PSI), in collaboration with the University of Connecticut (UConn), and with industry participation form Merck, proposes to develop and verify a fundamental model of Microwave- Assisted Freeze Drying (MAFD) to enable its implementation for pharmaceutical manufacturing. This effort will leverage primary drying models of traditional shelf-based freeze drying in vials developed and tested with support from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Our goal is to develop a heat and mass transfer model of the primary drying, or ice sublimation phase of MAFD freeze- drying, the most time consuming and critical phase. The model will predict the temperature of the product throughout primary drying and the drying time based on input parameters for the container system (e.g. vial, tray or dual chamber syringe), the product formulation (e.g. dielectric properties, resistance to drying, etc.), and the process conditions (e.g. microwave frequency, microwave power, chamber pressure). This program supports the advancement of regulatory science to facilitate the implementation of emerging manufacturing technology in the pharmaceutical sector. Microwave-assisted freeze drying (MAFD) is emerging as an alternative to traditional freeze drying as MAFD can significantly reduce processing costs and time compared to traditional freeze drying while maintaining product efficacy and stability. For example, studies have shown an approximately 80% reduction in cycle time using MAFD over traditional freeze drying. MAFD has more commonly been used in the food industry, and has not been applied to drying of pharmaceutical products at a large scale. This is partially due to a lack of knowledge of formulation response to microwave energy, and heat and mass transfer in MAFD processes to ensure efficient process design while maintaining product quality attributes. The successful completion of this program will result in a heat and mass transfer model of MAFD and a database of formulation microwave power absorption that can be used by industry to enable implementation of MAFD processes. Transitioning from traditional freeze drying to MAFD will result in reduced processing costs and cycle times and enable more agile manufacturing including on-demand and semi-continuous processes. This effort is particularly relevant during this current global pandemic. Administration of the current COVID-19 vaccines was limited by cold chain storage requirements. As COVID-19 vaccination programs transition from emergency response to routine administration, the economics of production and distribution will become more crucial. It is likely that future development of the COVID-19 vaccines will focus on freeze drying for product stabilization and distribution. Many common vaccines require freeze-drying, including those to prevent measles, yellow fever, Hib, BCG, H1N1, etc. Development of economical freeze-drying cycles will be critical for production of COVID-19 vaccines in manufacturing facilities around the world.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10350", "attributes": { "award_id": "1R43OH012495-01", "title": "Moisture-resistant, sterilizable and reusable N-95 like piezoelectric facemask filtering membrane with long-term biodegradability", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24462, "first_name": "BRIDGETTE E", "last_name": "GARRETT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 276415, "principal_investigator": { "id": 26312, "first_name": "Linh", "last_name": "Le", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26313, "first_name": "Thanh Duc", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1922, "ror": "", "name": "PIEZOBIOMEMBRANE, INC.", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Facemasks have been shown to be the most effective tool to prevent the spreading and transmission of infectious viruses in pandemics. Many countries, including the US, have enforced the use of facemasks in public area or healthcare settings to protect healthcare workers and general population against highly contagious viral strains of the SARS-COVID-2. This global enforcement of facemasks has led to billions of N95/surgical masks (which are intended for single-use and are non-degradable) being disposed of in landfills and ocean, causing a significant crisis on the environment. Aside from viral infection, particulate matters (PMs, i.e. small particles with sizes at nano or micro-meters) from the combustion of fossil fuels around the world also has severe impact on human health. Especially, small particles such as PM1.0 or PM2.5 (i.e. sizes < 1 µm and 2.5 µm, respectively) are the most poisonous and harmful ones since they can travel into deeper parts of the respiratory tract and even penetrate into the bloodstream. In this regard, facemasks have also been the most effective solution to protect public health from industrial PMs and air pollution. Given such a tremendous demand of filtration facemask membranes, the heavy and continuous use of traditional non-degradable, one-time disposable facemasks (e.g. N95 and surgical masks) will not only be an economic burden but also cause an environmental crisis with billions of permanent plastic wastes disposed every year. Besides the environmental problem, current facemasks struggle with a significant drawback of losing filtration function after a long period of continuous use and exposure of humid air, thus making the mask users non-protective against the risk of viral infection. Herein, we propose a novel piezoelectric composite nanofiber mesh of Poly-L-Lactide (PLLA) and Magnesium Oxide (MgO) which provides all properties of an ideal filtering membrane, including (1) moisture- resistance, (2) good mechanical strength, (3) N95-like filtering efficiency, (4) small pressure-drop, (5) reusability/sterilize-ability, and (6) long-term biodegradation to avoid any harm on the environment. Our major hypothesis is that by creating a highly piezoelectric MgO/PLLA and then employ multi-layer of the MgO/PLLA nanofiber mesh with tunable pore size/pore number in each layer, we will be able to produce a desired filter with a high filtration efficiency and low pressure drop, similar to a N95 facemask filter. To achieve the facemask and demonstrate the hypothesis in this phase I SBIR, we design the project with two aims. Aims 1 (6 months) is to characterize the MgO/PLLA nanofiber membrane filter in terms of piezoelectric effect, mechanical property, and porosity of the nanofiber membrane. Aim 2 (12 months) is to fabricate the multi-layer filtering membrane with the MgO/PLLA nanofiber mesh patterned with micro-pores and achieve the N-95 performance in terms of filtering efficiency and pressure drop.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10352", "attributes": { "award_id": "1R43OH012416-01", "title": "Regenerative face mask with long shelf life and long service time for effective coronavirus filtration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25093, "first_name": "Marcienne", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-02-28", "award_amount": 243500, "principal_investigator": { "id": 26316, "first_name": "Bo", "last_name": "li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1923, "ror": "", "name": "POLYK TECHNOLOGIES, LLC", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "PolyK Technologies, LLC SBIR Phase I The outbreak of COVID-19 causes a soaring increase in demand of N95 masks, which can effectively filter out over 95% of coronavirus. Despite the dramatic supply-demand gap has been temporarily suppressed by the use of vaccines, the virus mutation and the misinformation holding back people from receiving the vaccine add complexity to the battle against the COVID virus. Currently, the infection rate begins to rise sharply in several states, and the mask mandate is being reinstated. It is unclear whether the looming increase of mask demands can be fulfilled. The electrostatic filter is the key element rendering N95 masks effective against minuscular airborne containminats, but also the one limiting the service time of the N95 masks. N95 masks have to be discarded after daily use (once surface charges are dissipated) and cannot be resued by cleaning or disinfection. Inspired by our experience in piezoelectric polymers, this project will develop a novel piezo/pyro filter for N95 masks. The piezo/pyro filters can generate can continuously generate substantial surface charges during breathing, therefore enabling effective filtration against minuscular COVID virus even after repetitive sanitization and sterilization. This project will address any shortage of N95 masks and similar PPE once and for all, by providing genuine resuable piezo masks with with high filtration efficacy, long service time, and regeneration capability (reusable after disinfection without sacrificing the filtration performance).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10353", "attributes": { "award_id": "1U18FD007712-01", "title": "Building next generation sequencing capacity at Wisconsin Veterinary Diagnostic Laboratory for diagnosis of COVID-19 (SARS-CoV-2 infection) in animals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 47800, "principal_investigator": { "id": 24612, "first_name": "Ailam Lee", "last_name": "Lim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this proposal is to build viral whole genome sequencing capacity at the Wisconsin Veterinary Diagnostic Laboratory (WVDL) for sequencing of SARS‐CoV‐2 from animal samples. We are requesting funding for consumables, equipment, and personnel time to perform SARS‐CoV‐2 whole genome sequencing. We will purchase an IndiMag48S nucleic acids extraction platform, which is critical equipment for high‐quality samples preparation, and a nucleic acid workstation to use for library preparation. We will also purchase an Oxford Nanopore Flongle long read sequencing platform to provide cost effective capacity to sequence small sample caseloads without the need to batch samples. We will validate library preparation and sequencing protocols using published reagents in ARTIC protocol and a commercial NEBNext sequencing kit (New England BioLabs). A high computing power machine will be purchased to support the computation demand in bioinformatics analysis of the SARS‐ CoV‐2 sequencing data. We will develop and provide standard operating protocols and analysis programing to veterinary diagnostic personnel to maintain proficiency in sequencing and data analysis, and fast and economically efficient in SARS‐CoV‐2 genomic lineages determination. We will use these tools to train our staff and expand our capacity and capability to support diagnostic activities for the ongoing global SARS‐CoV‐2 pandemic. Additionally, this proposed work will indirectly improve WVDL's readiness for immediate impact and response during future animal and public health disease outbreaks.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10361", "attributes": { "award_id": "1R43OH012421-01", "title": "Enhancement to Leak Free Non-Invasive Ventilation Mask for Infectious Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25093, "first_name": "Marcienne", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-02-28", "award_amount": 259354, "principal_investigator": { "id": 26332, "first_name": "Daniel", "last_name": "Micka", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1508, "ror": "", "name": "CREARE, LLC", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true }, "abstract": "A large number of patients with infectious respiratory diseases such as COVID-19 and SARS require respiratory support. Noninvasive Positive Pressure Ventilation (NPPV) via a mask is an appropriate treatment for many patients that can lead to better outcomes than intubation. Additionally, the equipment used for NPPV (such as CPAP machines) is widely available, making NPPV well suited for responding to outbreaks and pandemics. Unfortunately, NPPV masks increase the risk of disease transmission by spreading contaminated aerosols leaking from the mask seal. This exposes health care workers and other patients to increased risk and can hamper efforts to contain outbreaks of infectious diseases. The objective of this program is to develop an innovative NPPV patient interface that eliminates the leakage of contaminated aerosols through the mask seal. We propose to enhance Creare's novel leak-free mask technology to make it easier and more practical to use in a critical care setting. Our device will be cost effective and integrate easily with existing CPAP machines widely used in hospitals. This will enable widespread use of NPPV therapy on infectious patients while protecting health care workers and other patients. This technology will be a critical tool for treating patients while preventing the spreading of infectious respiratory diseases in a hospital setting. In the Phase I program, we will demonstrate the viability of our enhanced technology through building and testing laboratory prototypes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10371", "attributes": { "award_id": "1U01FD007769-01", "title": "DDT-BMQ-000079 Establishing Performance Characteristics of the Epidermal Neurite Density (END) Biomarker to Assist Diagnosis of Small Fiber Neuropathy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26344, "first_name": "York", "last_name": "Tomita", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 248415, "principal_investigator": { "id": 26345, "first_name": "Anne Louise LOUISE", "last_name": "Oaklander", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "In the polyneuropathies, adverse conditions damage the body’s peripheral neurons, causing them to fire dysfunctionally and sometimes begin to degenerate. Small-fiber neuropathy (SFN) is a very common type. Many neuropathies, including from diabetes or toxic exposures, often affect the ends of smaller fibers earliest or most severely. Sensory, chronic tingling, itch, and numbness, typically starting in the feet and lower legs then spreading upwards are external symptoms of SFN. However, as most of the autonomic axons that innervate and regulate the body systems are also small-diameter fibers, SFN also causes internal symptoms–intolerance of usual level of exertion, profound fatigue, lightheadedness, rapid heart rate, and gastrointestinal symptoms. SFN is not detected by the standard diagnostic biomarker for large-fiber neuropathies (electromyography and nerve conduction study). Instead, END (epidermal neurite density) measurements are made from tiny punch biopsies from the lower leg. Along with clinical indicators, this biomarker is validated to identify suspected cases. Skin biopsy testing is integral to the first formal case definition of SFN from uncertain cause, formulated by a global expert ACTTION Committee meeting supported by FDA, NIH, and industry. This group, that included the P.I., recommended END measurement as mandatory for clinical trial inclusion (Freeman, R. et al. Neurology, 2020). Hence this request for biomarker qualification for a diagnostic test increasingly used including for clinical and treatment research, despite sometimes varying methodological details and analyses between accredited university and commercial U.S. labs. Any inconsistencies increase risk that the same biopsy could generate different END numbers and/or divergent interpretations. Clinical research studies using END measurements for inclusion or outcomes might enroll slightly different participants or generate different efficacy data that could influence FDA approval. In 2022, Dr. Oaklander and others linked SFN to long-COVID illnesses, so long-COVID studies including NIH’s RECOVER are considering adding END measurement. The objective of the proposed studies is to identify and then validate best methods of obtaining and analyzing the END biomarker. The Aims respond to the applicants’ DDTBMQ000079 LOI approval to generate a full Biomarker Qualifier Plan. Aim I analyzes anonymized END measurements and other data from a large US diagnostic skin biopsy lab dataset of healthy controls and patients to identify knowledge gaps, then compare and validate potential solutions. Aim II adds prospective biopsies where needed. Aim III includes other stakeholders including outside accredited labs for cross-validation and neurological societies to generate Guidelines. Standard operating procedures would be improved throughout, and statistical modeling for END distribution, including selection of variables and algorithms, would be optimized and validated.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10380", "attributes": { "award_id": "1R03OH012395-01", "title": "Longitudinal Trajectories of Workplace Violence and Worker Health Among Child Protective Services Workers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24557, "first_name": "Sharon", "last_name": "Chiou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-08-31", "award_amount": 77000, "principal_investigator": { "id": 26358, "first_name": "Melissa", "last_name": "Radey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 343, "ror": "https://ror.org/05g3dte14", "name": "Florida State University", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Workplace violence, or the act or threat of verbal abuse or physical violence directed toward workers completing their jobs, is rampant and harmful to workers in the health and social assistance sector. Estimates suggest that 62% to 97% of these workers experience violence in their careers. Moreover, violence in the sector has risen over the last decade, and, an apparent surge during the Coronavirus pandemic poses an “international emergency” undermining health systems. The human and economic tolls of workplace violence are high including physical injury, psychological illness, lost productivity, and lower service quality. Workers in this sector have a non-fatal workplace injury rate 5 times that of all U.S. workers (10.4 vs. 2.1 per 10,000 workers) and account for 73% of U.S. workplace injuries. One group in this sector, Child Protective Services (CPS) workers, responsible for investigating and providing services to families with alleged or verified child abuse or neglect, are particularly vulnerable to violence, specifically client violence in which the perpetrator becomes violent while receiving client services. The nature of CPS work (e.g., threat of child removal, hostile clients, dangerous neighborhoods) places workers in unique and violent-prone environments. The overall goal of this project is to examine the longitudinal prevalence and health consequences of client violence among CPS workers. Specifically, this study aims to (1) determine the 3-year longitudinal trajectories of client violence by subtype (i.e., verbal abuse, threat, physical); (2) test the role of client violence in predicting worker health over time; and (3) determine the extent to which client violence trajectories and job demands and supports interact to influence workers’ health trajectories. We will use data from the Florida Study of Professionals for Safe Families (FSPSF), a statewide, longitudinal cohort study of CPS workers (N = 1,500) that we collected to provide insight into CPS work and worker wellbeing. This project is significant because it responds to NIOSH’s (2019) Strategic Goal 1 by tracking work-related injuries and illnesses and generating knowledge to inform intervention strategies. Moreover, analyzing worker attributes; job demands and supports; violence type and accumulation; and health consequences addresses NORA’s (2019) Research Agenda Objective 3 by examining the epidemiology of workplace violence and identifying strategies for prevention and mitigation. The project offers conceptual innovation by examining client violence and worker health longitudinally among a cohort of CPS workers over the first three years on the job, the time of highest turnover and increased risk of violence. Our use of advanced statistical longitudinal modeling to provide stronger evidence of explanatory pathways not determined in current research is methodologically innovative. The frequency and intensity of client violence among the health and social assistance sector and its potential role in worker health amplify the need to examine violence, its accumulation over worker tenure, and the consequences for worker health.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10381", "attributes": { "award_id": "1R43OH012358-01", "title": "Anti-viral Active Air-Purifying Respirator with Photocatalytic Microreactor to Prevent Airborne Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25093, "first_name": "Marcienne", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 243500, "principal_investigator": { "id": 26359, "first_name": "M Arifur ARIFUR", "last_name": "Rahman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1927, "ror": "", "name": "HAWAI'I INNOVATION LABORATORY, INC.", "address": "", "city": "", "state": "HI", "zip": "", "country": "United States", "approved": true }, "abstract": "The potential for an epidemic or pandemic caused by a high-impact respiratory pathogen is increasing. Studies prior to the COVID-19 outbreak show that the frequency of outbreaks of newly emerging diseases rose, which has exacerbated since the pandemic started. Respiratory protective masks are used whenever airborne contaminants such as dust, fumes, smoke, and mists are present in the air. The contaminants also include airborne bacteria, viruses, and fungi. Currently, most commercially available untethered protective masks are designed for surgical or industrial safety and may provide adequate protection from airborne contaminants but do so through particle filtering. Therefore, most masks do not kill the pathogens to protect the wearers. Hence, while using an active respirator, the filtered pathogens, which are alive and infectious, may enter the respiratory tract overtime or spread by touch. The current active respirators are bulky, heavy, and designed for 2-4 hours of use. In brief, the protective masks are not designed for prolonged daily use by untrained users. Until the outbreak of COVID-19, the necessity of an anti-pathogenic wearable respirator was not as significant as it is now. This COVID-19 has exposed our lack of preparedness in providing a safe working environment for the frontline workers during the respiratory pandemic. Most current protective respirators address only part of the desired solution. A working solution needs to combine all the critical requirements, such as high filtration (≥ 99%) for nanometer-scale particles, pathogens-neutralization, moisture dissipation, eco-friendliness, and comfortable prolonged use. The proposed R&D effort addresses a wearable anti-pathogenic respirator's critical need for prolonged use by trained or untrained users. We propose designing and developing an active, untethered, anti- pathogen full-face breathing mask with an integrated photocatalytic microreactor that can neutralize all microorganisms, including viruses SARS-CoV-2. Although the proposed system contains all the components of a portable respirator, the components are miniaturized and integrated into a full-face mask. Hence, the system is referred to as a full-face mask in this proposal. The proposed full-face mask intakes surrounding air filters out particles as small as 100 nm (size of a single SARS-CoV-2 viral particle), passes the air through an integrated photocatalytic microreactor killing all the microorganisms, and volatile organic chemicals (VOCs), and supply clean air to the user. The mask also works as a defense against the threat of contamination of ventilation systems by bioterrorism. The mask is completely untethered and designed to run for 8-10 hours with a single charge. The active-powered mask can save the wearer from airborne pathogens while maintaining visibility and comfort.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10382", "attributes": { "award_id": "1U18FD007730-01", "title": "COVID-19: Enhancing testing and sequencing capacity for Severe Acute Respiratory Syndrome Coronavirus 2 and other zoonotic viruses at the Minnesota Veterinary Diagnostic Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 89694, "principal_investigator": { "id": 26360, "first_name": "Albert", "last_name": "Rovira", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "Enhancing testing and sequencing capacity for Severe Acute Respiratory Syndrome Coronavirus 2 and other zoonotic viruses at the Minnesota Veterinary Diagnostic Laboratory The Minnesota Veterinary Diagnostic Laboratory (MVDL) has the capability of testing for SARS-CoV-2 by PCR. The MVDL was critical during the first phase of the response to the pandemic by testing human samples while the state of Minnesota acquired the capacity to respond to the testing needs. The MVDL is the reference laboratory for SARS-CoV-2 testing in animal samples in Minnesota. This proposal requests funding for equipment to improve laboratory capacity to test for SARS-CoV-2 by PCR and to sequence positive samples. These improvements would also benefit the capacity to respond to other zoonotic diseases. The SARS-CoV-2 PCR test is currently performed in an Applied Biosystems 7500 thermal cycler, which can test 93 samples at a time. To improve the efficiency of the process, we propose to purchase a Quantstudio 6 Pro thermal cycler, which can process 378 samples at a time. Sequencing of SARS-Co-2-positive samples is an important component of disease surveillance. Sequencing allows for identification of new variants and monitoring of variants of concern. The MVDL performs routine sequencing for multiple viral pathogens, and could easily start sequencing SARS-CoV-2 if needed. The MVDL has expertise sequencing viruses from a wide variety of specimens, some with low amounts of DNA/RNA. The initial PCR amplification step performed as part of the sequencing process is currently done with ABI 9700 GenAmp PCR instruments, which are old and do not have maintenance and repair parts available anymore. Therefore, we propose to purchase a Proflex 96-well thermal cycler from Life Technologies/Thermo Fisher. The addition of this instrument will add sequencing capacity to the lab so SARS-CoV-2 sequencing can be performed in addition to the routine sequencing procedures currently being run.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1382, "pages": 1419, "count": 14184 } } }